guidelin
present
basic
principl
antibiot
use
acut
upper
respiratori
infect
adult
age
year
older
consider
south
korea
current
state
affair
march
physician
use
guidelin
refer
provid
individu
care
patient
basi
univers
applic
adult
patient
guidelin
use
standard
criterion
determin
adequaci
clinician
final
decis
guidelin
may
use
person
care
educ
purpos
may
use
commerci
care
evalu
purpos
case
parti
wish
use
guidelin
purpos
provid
care
educ
written
request
submit
committe
obtain
written
approv
acut
upper
respiratori
infect
uri
common
diseas
among
adult
gener
experi
acut
uri
two
five
time
year
accord
data
unit
state
us
acut
uri
associ
high
diseas
burden
account
work
absenc
among
adult
worker
outpati
emerg
depart
visit
acut
uri
refer
acut
infect
nose
sinu
pharynx
middl
ear
larynx
epiglotti
airway
bronchu
common
cold
frequent
uri
howev
infect
clinic
diagnos
base
predomin
symptom
accord
anatom
locat
sever
infiltr
word
uri
classifi
pharyng
tonsil
character
sore
throat
laryng
epiglott
character
hoars
rhinosinus
character
sinusrel
symptom
case
otiti
media
tracheiti
bronchiti
also
classifi
acut
uri
common
cold
may
caus
variou
pathogen
virus
symptom
includ
mild
fever
nasal
discharg
nasal
congest
sneez
sore
throat
cough
muscl
ach
common
cold
usual
resolv
natur
requir
symptomat
therapi
certain
case
antibiot
use
warrant
well
known
use
antibiot
common
cold
ineffect
reduc
complic
bacteri
infect
also
increas
medic
cost
induc
side
effect
resist
antibiot
avoid
antibiot
use
common
cold
import
nation
healthcar
issu
must
stress
prevent
antibiot
abus
also
use
qualiti
index
health
care
institut
tonsil
adult
caus
bacteria
streptococcu
pyogen
group
betahemolyt
streptococci
patient
may
develop
acut
bacteri
rhinosinus
viral
respiratori
infect
acut
bronchiti
may
caus
bacteria
bordetella
pertussi
mycoplasma
pneumonia
chlamydophila
pneumonia
therefor
appropri
use
antibiot
requir
case
acut
uri
random
control
trial
rct
rare
upper
respiratori
infecti
diseas
studi
find
controversi
mani
case
hamper
evidencebas
care
refer
standard
care
guidelin
even
exist
evidencebas
guidelin
countri
featur
vari
stanc
context
korean
societi
chemotherapi
korean
societi
infecti
diseas
korean
societi
otorhinolaryngologyhead
neck
surgeri
korean
associ
otorhinolaryngologist
korean
associ
famili
medicin
korean
medic
practition
associ
nation
evidencebas
healthcar
collabor
agenc
develop
guidelin
antibiot
use
adult
upper
respiratori
infect
guidelin
aim
promot
appropri
use
antibiot
primari
care
physician
care
upper
respiratori
infect
guidelin
present
basic
principl
antibiot
use
adult
patient
suspect
uri
consider
current
situat
korea
march
particular
focu
bacteri
pharyngotonsil
bacteri
sinus
requir
antibiot
plan
regularli
revis
guidelin
accord
futur
chang
korea
januari
committe
establish
develop
antibiot
guidelin
uri
adult
clinic
care
guidelin
design
focu
key
question
kq
help
clinician
find
solut
clinic
question
face
treat
patient
acut
pharyngotonsil
sinus
total
key
question
five
acut
pharyngotonsil
five
acut
sinus
chosen
context
domest
situat
meet
among
member
guidelin
develop
committe
nomin
group
techniqu
gener
use
reach
consensu
per
grade
grade
recommend
assess
develop
evalu
http
wwwgradeworkinggroup
org
approach
qualiti
evid
classifi
high
moder
low
low
wherea
strength
recommend
classifi
strong
weak
tabl
guidelin
develop
guidelin
develop
committe
present
korean
societi
chemotherapi
april
expert
opinion
collect
base
discuss
revis
made
guidelin
meet
among
member
develop
committe
opinion
expert
group
addit
collect
base
guidelin
final
guidelin
present
technic
term
korean
languag
accord
fifth
revis
medic
terminolog
korean
medic
associ
revis
novemb
correspond
english
term
ad
parenthes
mean
clearli
convey
use
korean
term
term
present
korean
name
pathogen
proper
noun
name
drug
unit
written
english
firstlin
treatment
refer
first
round
antibiot
therapi
secondlin
treatment
refer
chang
antibiot
firstlin
treatment
deem
fail
univers
use
antibiot
patient
sore
throat
benefici
term
shorten
length
acut
pharyngotonsil
symptom
reduc
frequenc
bacteri
complic
howev
use
may
heighten
preval
side
effect
facilit
spread
antimicrobialresist
bacteria
therebi
increas
medic
cost
therefor
antibiot
prescript
avoid
acut
viral
pharyngotonsil
appropri
antimicrobi
therapi
administ
acut
bacteri
pharyngotonsil
base
aggress
differenti
caus
pathogen
clinic
set
common
caus
acut
bacteri
pharyngotonsil
pyogen
account
case
acut
bacteri
pharyngotonsil
adult
pyogenesinduc
acut
pharyngotonsil
may
lead
acut
suppur
complic
otiti
media
peritonsillar
abscess
well
nonsuppur
complic
rheumat
fever
acut
glomerulonephr
therefor
prompt
diagnosi
appropri
antimicrobi
therapi
necessari
although
acut
rheumat
fever
consider
less
preval
today
clinic
signific
substanti
group
c
g
betahemolyt
streptococci
c
pneumonia
pneumonia
arcanobacterium
haemolyticum
corynebacterium
diphtheria
fusobacterium
necrophorum
neisseria
gonorrhea
treponema
pallidum
francisella
tularensi
also
rare
pathogen
acut
pharyngotonsil
historytak
physic
examin
throat
swab
cultur
rapid
antigen
test
help
differenti
caus
pathogen
acut
pharyngotonsil
symptom
nasal
drainag
nasal
congest
cough
conjunct
hoars
diarrhea
oral
ulcer
bullou
oral
lesion
suggest
viral
bacteri
acut
pharyngotonsil
hand
symptom
swallow
difficulti
dysphagia
sore
throat
fever
headach
strength
recommend
qualiti
evid
relat
comorbid
diagnos
provid
treatment
accord
guidelin
morbid
consid
environment
therapi
immun
therapi
drug
therapi
patient
hypersensit
although
differenti
pathogen
base
clinic
symptom
sign
produc
high
concord
among
physician
sensit
specif
predict
posit
throat
swab
cultur
test
rang
respect
even
among
highli
experienc
physician
varieti
clinic
predict
tool
propos
although
associ
limit
diagnost
accuraci
practic
commonli
use
clinic
instrument
centor
criteria
first
suggest
use
adult
score
symptom
sign
modifi
centor
criteria
mclsaac
criteria
addit
age
criteria
propos
fig
modifi
centor
criteria
mcisaac
criteria
clinic
predict
model
classifi
likelihood
pyogen
infect
tabl
although
vari
relat
preval
pyogen
infect
centor
score
higher
show
posit
predict
valu
neg
predict
valu
diagnosi
pyogen
infect
use
throat
swab
cultur
sensit
specif
nation
institut
health
care
excel
nice
guidelin
recommend
antibiot
prescript
three
centor
criteria
prior
studi
report
antibiot
therapi
depend
presenc
three
four
centor
criteria
conduc
improv
symptom
prevent
complic
well
reduc
inappropri
use
antibiot
present
guidelin
recommend
clinician
use
modifi
centor
criteria
accord
guidelin
publish
infecti
diseas
societi
america
idsa
difficult
differenti
pyogenesinduc
pharyngotonsil
viral
pharyngotonsil
mere
base
clinic
manifest
guidelin
recommend
rapid
antigen
diagnost
test
radt
bacteri
cultur
case
suggest
pyogenesinduc
pharyngotonsil
except
case
viral
diseas
highli
suspect
pharyngotonsil
caus
pyogen
diagnos
pyogen
identifi
use
radt
cultur
test
throat
swab
throat
swab
follow
step
figur
radt
conveni
test
perform
provid
result
point
care
sensit
specif
vari
depend
patient
test
method
rang
respect
compar
cultur
test
throat
swab
cultur
perform
radt
neg
perform
test
gener
recommend
adult
radt
posit
patient
diagnos
pharyngotonsil
caus
pyogen
without
bacteri
cultur
data
radt
korea
gener
involv
children
studi
report
test
use
necessari
use
activ
proper
use
antibiot
antistreptolysin
aso
titer
may
use
diagnosi
nonsuppur
complic
acut
rheumat
fever
acut
glomerulonephr
howev
titer
reach
peak
level
week
onset
continu
rise
sever
month
aso
use
diagnosi
acut
pharyngotonsil
gener
patient
acut
pharyngotonsil
elev
creactiv
protein
total
white
blood
cell
count
neutrophil
granulocyt
count
aso
test
low
sensit
specif
diagnos
acut
bacteri
pharyngotonsil
adult
procalcitonin
erythrocyt
sediment
rate
also
use
differenti
acut
bacteri
pharyngotonsil
one
report
suggest
use
creactiv
protein
level
mgl
mgdl
clinic
score
may
help
diagnos
acut
bacteri
pharyngotonsil
howev
blood
test
gener
recommend
patient
suspect
acut
pharyngotonsil
nice
guidelin
suggest
antibiot
prescript
pyogen
infect
depend
patient
state
patient
three
centor
criteria
hand
idsa
recommend
clinician
prescrib
antibiot
accur
bacteriolog
diagnosi
present
guidelin
recommend
antibiot
prescrib
acut
pharyngotonsil
patient
complic
patient
modifi
centor
score
mcisaac
score
patient
posit
radt
radt
perform
antimicrobi
therapi
may
consid
depend
modifi
centor
score
mcisaac
score
fig
recent
largescal
cohort
studi
report
delay
antibiot
therapi
led
reduct
suppur
complic
similar
produc
immedi
antibiot
therapi
tenday
amoxicillin
therapi
may
use
howev
amoxicillin
may
use
infecti
mononucleosi
suspect
qualiti
evid
high
strength
recommend
strong
fiveday
cefdinir
azithromycin
therapi
may
use
case
poor
patient
complianc
case
antimicrobi
therapi
may
difficult
patient
acut
bacteri
pharyngotonsil
may
also
caus
divers
type
bacteria
pyogen
therefor
appropri
antibiot
chosen
consider
type
pathogen
treat
antibiot
suscept
spectrum
antibiot
side
effect
patient
underli
diseas
drug
interact
cost
us
european
clinic
figur
take
throat
swab
press
tongu
tongu
depressor
reveal
palatin
tonsil
uvula
without
touch
uvula
place
steril
swab
deep
insid
throat
past
uvula
gentli
stroke
one
palatin
tonsil
posterior
nasopharynx
palatin
tonsil
order
specifi
collect
sampl
lesion
exud
area
sampl
collect
care
touch
area
mouth
tongu
inner
cheek
contamin
swab
saliva
immedi
place
swab
steril
tube
send
laboratori
care
guidelin
pharyngotonsil
recommend
penicillin
v
firstlin
antibiot
therapi
date
penicillin
resist
found
clinic
isol
pyogen
acut
pharyngotonsil
specimen
korea
global
betalactam
resist
pyogen
rare
report
unlik
increas
antimicrobi
resist
among
bacteria
penicillin
use
antibiot
avail
firstlin
therapi
bacteri
pharyngotonsil
costeffect
narrowspectrum
antibiot
whose
efficaci
proven
longaccumul
data
howev
oral
penicillin
v
produc
distribut
korea
amoxicillin
use
firstlin
antibiot
instead
tabl
multicent
studi
conduct
franc
report
amoxicillin
therapi
penicillin
v
therapi
differ
significantli
therapeut
efficaci
safeti
among
patient
acut
pharyngotonsil
prospect
observ
studi
conduct
us
also
report
amoxicillin
superior
penicillin
microbi
respons
clinic
efficaci
amoxicillin
particularli
benefici
penicillin
despit
wider
microbiolog
spectrum
higher
oral
bioavail
even
taken
togeth
food
oncedaili
administr
help
improv
patient
complianc
howev
amoxicillin
must
use
case
involv
infecti
mononucleosi
caus
ebv
induc
drug
rash
case
secondlin
antibiot
may
consid
case
sinc
benzathin
penicillin
g
inject
along
penicillin
v
use
firstlin
therapi
acut
bacteri
pharyngotonsil
american
heart
associ
idsa
also
recommend
im
inject
benzathin
penicillin
g
addit
penicillin
v
compar
inject
antibiot
oral
antibiot
associ
fewer
complic
less
sever
hypersensit
reaction
pain
inject
site
howev
drug
complianc
may
problem
therefor
im
benzathin
penicillin
g
may
use
patient
deem
difficulti
compli
oral
antibiot
regimen
studi
found
signific
differ
clinic
efficaci
amoxicillin
oral
antibiot
therapi
singl
im
inject
benzathin
penicillin
g
patient
type
penicillin
hypersensit
eg
rash
firstgener
cephalosporin
cephalexin
cefadroxil
therapi
clindamycin
clarithromycin
therapi
azithromycin
therapi
cefdinir
cefpodoxim
therapi
may
use
tabl
type
betalactam
antibiot
eg
cephalosporin
use
patient
type
hypersensit
eg
anaphylaxi
tabl
studi
found
broadspectrum
cephalosporin
therapi
slightli
better
efficaci
penicillin
v
treatment
howev
therapi
use
cefdinir
cefpodoxim
gener
consid
use
firstlin
therapi
owe
rel
higher
cost
wider
antibiot
spectrum
tabl
gener
firstlin
therapi
bacteri
pharyngotonsil
penicillin
v
amoxicillin
includ
antibiot
pyogen
treatment
respons
within
hour
administr
improv
clinic
symptom
within
day
treatment
respons
within
hour
administr
firstlin
treatment
deem
failur
follow
review
first
check
drug
complianc
second
although
penicillinresist
rare
pyogen
ampicillinsulbactam
amoxicillinclavulan
narrowspectrum
cephalosporin
clindamycin
may
consid
secondlin
antibiot
review
patient
recent
histori
antibiot
therapi
tabl
tenday
cephalexin
therapi
amoxicillin
daili
therapi
led
significantli
differ
treatment
outcom
data
therapeut
outcom
ampicillinsulbactam
amoxicillinclavulan
limit
penicillin
popular
firstlin
antibiot
therapi
owe
proven
clinic
efficaci
safeti
low
cost
howev
grow
popular
macrolid
erythromycin
clindamycin
respons
concern
hypersensit
penicillin
led
increas
resist
antimicrobi
among
pyogen
strain
macrolid
resist
among
pyogen
strain
isol
patient
acut
pharyng
live
jinju
korea
reach
erythromycin
resist
seoul
masan
respect
resist
erythromycin
azithromycin
clindamycin
increas
respect
therefor
macrolid
clindamycin
recommend
firstlin
antibiot
treatment
failur
assess
use
third
addit
pyogen
acut
pharyngotonsil
may
caus
varieti
pathogen
includ
ebv
adenoviru
mycoplasma
fusobacterium
spp
corynebacterium
diphtheria
acanobacterium
haemolyticum
n
gonorrhoea
rash
develop
amoxicillin
administr
may
suggest
ebv
infect
fusobacterium
infect
treat
ampicillinsulbactam
ampicillin
metronidazol
penicillinresist
fusobacterium
spp
report
rare
case
penicillin
erythromycin
recommend
antibiot
therapi
c
diphtheria
infect
acut
tonsil
caus
n
gonorrhoea
followup
bacteri
cultur
recommend
treatment
complet
owe
difficulti
complet
remov
microorgan
infect
treat
ceftriaxon
singl
dose
mg
im
secondlin
antimicrobi
therapi
may
consid
pyogen
repeatedli
detect
cultur
infect
recur
addit
detail
delin
key
question
suppur
complic
acut
pharyngotonsil
includ
peritonsillar
abscess
parapharyng
abscess
lymphnod
sinus
otiti
media
mastoid
necrot
fasciiti
toxic
shock
syndrom
deep
abscess
head
neck
treat
combin
secondor
thirdgener
cephalosporin
eg
ceftriaxon
cefuroxim
clindamycin
ampicillinsulbactam
needl
aspir
incis
drainag
activ
consid
treatment
pathogen
identif
purpos
rare
case
fusobacterium
spp
may
also
induc
lemierr
syndrom
caus
septic
thrombophleb
intern
jugular
vein
nonsuppur
complic
pyogen
infect
includ
rheumat
fever
acut
glomerulonephr
tient
frequent
recurr
episod
appar
bacteri
pharyngotonsil
prophylact
antibiot
therapi
recommend
recurr
bacteri
pharyngotonsil
qualiti
evid
high
strength
recommend
weak
recurr
acut
bacteri
pharyngotonsil
may
treat
firstlin
antibiot
narrowspectrum
cephalosporin
cephradin
cefadroxil
clindamycin
amoxicillinclavulan
penicillin
rifampin
combin
therapi
may
consid
secondlin
therapi
qualiti
evid
high
strength
recommend
weak
acut
bacteri
pharyngotonsil
may
recur
despit
antibiot
therapi
owe
inappropri
use
antibiot
insuffici
antibiot
dosag
treatment
durat
low
patient
complianc
reinfect
though
rare
penicillin
resist
may
consid
case
pyogen
colon
continu
acut
upper
respiratori
infect
due
viral
pathogen
bacteri
cultur
perform
complet
antibiot
therapi
pyogen
infect
symptom
persist
recurr
suspect
patient
histori
rheumat
fever
acut
glomerulonephr
cultur
gener
perform
within
day
treatment
complet
treatment
failur
chronic
carrier
must
distinguish
antibiot
administ
symptom
improv
even
bacteri
strain
isol
followup
test
howev
patient
histori
famili
histori
rheumat
fever
subject
retreat
even
asymptomat
symptom
persist
firstlin
antibiot
may
use
benzathin
penicillin
g
may
consid
patient
low
complianc
howev
establish
data
lack
treatment
failur
penicillin
secondlin
therapi
may
involv
narrowspectrum
cephalosporin
cephradin
cefadroxil
clindamycin
amoxicillinclavulan
combin
penicillin
rifampin
broadspectrum
cephalosporin
eg
cefprozil
cefuroxim
axetil
cefdinir
cefditoren
cefpodoxim
cefaclor
gener
recommend
owe
high
cost
wide
microbiolog
spectrum
one
studi
report
cefaclor
therapi
similar
clinic
effect
amoxicillinclavulan
acut
bacteri
pharyngotonsil
incid
digest
tract
side
effect
lower
former
treatment
group
moreov
cefaclor
therapi
amoxicillin
therapi
similar
treatment
effect
hand
treatment
respons
cefaclor
therapi
superior
erythromycin
treatment
report
attribut
macrolidesresist
pyogen
strain
addit
treatment
respons
cefditoren
pivoxil
therapi
amoxicillin
therapi
significantli
differ
previou
rct
investig
whether
antibiot
therapi
patient
acut
pharyngotonsil
reduc
incid
futur
episod
pharyngotonsil
whether
prophylact
antibiot
therapi
reduc
recurr
episod
pharyngotonsil
one
studi
prophylact
use
benzathin
penicillin
g
children
led
lower
incid
pyogenesinduc
pharyng
period
administr
compar
incid
period
administr
howev
studi
flaw
administ
placebo
control
group
prolong
azithromycin
therapi
altern
tonsillectomi
ineffect
treat
frequent
recurr
tonsil
anoth
studi
prophylact
use
cefpodoxim
proxetil
children
reduc
incid
acut
pharyngotonsil
month
compar
group
receiv
prophylact
treatment
howev
studi
limit
children
show
risk
antimicrobi
resist
shortterm
treatment
progress
necessit
longterm
studi
summari
one
three
previou
studi
suggest
prophylact
antibiot
therapi
ineffect
remain
two
studi
show
small
statist
signific
effect
howev
difficult
gener
find
due
methodolog
limit
studi
also
report
use
cephalosporin
treatment
prevent
purpos
lower
incid
sore
throat
macrolid
azithromycin
produc
similar
effect
presum
acut
bacteri
pharyngotonsil
suppur
complic
pharyngotonsil
acut
complic
pharyngotonsil
consid
patient
show
sever
persist
symptom
difficulti
swallow
hot
potato
voic
along
clinic
symptom
impli
airway
obstruct
case
patient
refer
specialist
determin
whether
surgic
treatment
indic
qualiti
evid
low
strength
recommend
strong
peritonsillar
abscess
common
deep
neck
infect
deep
neck
infect
includ
parapharyng
abscess
retropharyng
abscess
infect
para
pharyng
space
may
occur
complic
pharyng
furthermor
diseas
must
differenti
pharyngotonsil
begin
peritonsillar
cellul
phlegmon
term
use
case
peritonsillar
space
infect
without
format
abscess
peritonsillar
abscess
account
deep
neck
infect
common
among
adult
adolesc
possibl
children
import
manag
strategi
deep
neck
infect
airway
assess
manag
patient
restless
swallow
difficulti
drool
airway
close
observ
ensur
patenc
patient
assess
determin
whether
need
procedur
intub
proper
procedur
perform
refer
specialist
seriou
clinic
symptom
sign
list
tabl
ultrasound
comput
tomographi
ct
may
requir
ultrasound
perform
skill
expert
although
ct
associ
potenti
advers
effect
radiat
exposur
use
contrast
agent
perform
quickli
facil
equip
ct
scan
provid
object
imag
ct
commonli
perform
diagnosi
differenti
diagnosi
diseas
magnet
reson
imag
mri
may
also
use
abscess
neck
associ
teeth
mani
adult
common
complic
tonsil
among
children
adolesc
young
adult
immunocompromis
individu
may
nonrespons
tonsil
caus
variou
unusu
pathogen
import
refer
specialist
broader
approach
identifi
caus
effect
treatment
tabl
show
comparison
guidelin
korean
guidelin
antibiot
use
children
acut
upper
respiratori
tract
infect
major
guidelin
acut
pharyngotonsil
caus
pyogen
suggest
idsa
sinus
inflamm
nasal
passag
muco
tabl
definit
acut
sinus
acut
sinus
u
p
week
purul
nasal
drainag
anterior
posterior
accompani
nasal
obstruct
facial
painpressureful
purul
nasal
discharg
cloudi
color
contrast
clear
secret
typic
accompani
viral
upper
respiratori
infect
may
report
patient
observ
physic
examin
nasal
obstruct
may
report
patient
nasal
obstruct
congest
blockag
stuffi
may
diagnos
physic
examin
facial
painpressureful
may
involv
anterior
face
periorbit
region
manifest
headach
local
diffus
cute
sinus
caus
presum
caus
viral
infect
clinician
diagnos
viral
rhinosinus
symptom
sign
acut
sinus
present
less
day
symptom
worsen
acut
bacteri
sinus
cute
sinus
caus
presum
caus
bacteri
infect
clinician
diagnos
acut
bacteri
rhinosinus
symptom
sign
acut
sinus
fail
improv
within
day
beyond
onset
upper
respiratori
symptom
symptom
sign
acut
sinus
worsen
within
day
initi
improv
doubl
worsen
sa
line
sinus
result
infect
allergi
autoimmun
usual
accompani
inflamm
nasal
caviti
paranas
sinus
sinus
also
commonli
refer
rhinosinus
sinus
may
classifi
accord
main
site
infect
maxillari
frontal
ethmoid
sphenoid
sinus
also
classifi
accord
stage
infect
acut
less
week
subacut
month
chronic
month
moreov
sinus
classifi
communityacquir
healthcareassoci
nosocomi
infect
depend
locat
pathogen
exposur
detail
definit
acut
sinus
given
tabl
addit
identifi
infecti
caus
sinus
differenti
noninfecti
caus
import
vasomotor
atroph
sinus
well
recent
increas
allerg
sinus
infecti
caus
sinus
encompass
varieti
microorgan
includ
virus
bacteria
fungal
organ
bacteri
caus
account
viral
infect
account
remain
case
acut
viral
sinus
case
may
progress
acut
bacteri
sinus
bacteri
pathogen
identifi
needl
biopsi
maxillari
sinu
specimen
patient
acut
sinus
includ
pneumonia
h
influenza
anaerob
bacteria
streptococc
speci
catarrhali
staphylococcu
aureu
known
viral
pathogen
includ
rhinoviru
parainfluenza
viru
influenza
viru
though
rare
fungal
pathogen
aspergillu
zygomycet
phaeohyphomyci
pseudallescheria
hyalohyphomyci
also
identifi
acut
sinus
adult
includ
acut
communityacquir
bacteri
sinus
show
improv
symptom
within
day
without
antibiot
therapi
howev
bacteri
sinus
gener
requir
antibiot
therapi
sinus
normal
steril
environ
addit
certain
type
acut
bacteri
sinus
may
lead
sever
complic
bacteri
encephalomening
brain
abscess
periocular
tissu
infect
possibl
chronic
sinu
diseas
complet
elimin
fact
proper
antibiot
therapi
acut
communityacquir
bacteri
sinus
lead
erad
rate
sinus
superior
inappropri
antibiot
therapi
group
howev
inappropri
antibiot
therapi
increas
antimicrobi
resist
drug
side
effect
therebi
elev
medic
cost
situat
call
effort
differenti
acut
viral
bacteri
sinus
clinic
set
unfortun
difficult
differenti
acut
viral
sinus
acut
bacteri
sinus
clinic
set
owe
low
agreement
among
examin
imag
laboratori
find
use
diagnosi
addit
clinic
symptom
acut
sinus
nasal
congest
nasal
drainag
sneez
nose
itch
nevertheless
clinician
must
tri
differenti
viral
bacteri
sinus
base
symptom
sign
well
typic
manifest
chronolog
chang
symptom
although
needl
aspir
cultur
sinu
specimen
may
perform
diagnos
acut
bacteri
sinus
clinician
gener
make
clinic
diagnos
method
invas
techniqu
perform
clinic
set
clinic
diagnosi
acut
bacteri
sinus
gener
requir
progress
observ
day
radiolog
test
may
aid
clinic
diagnosi
symptom
purul
nasal
drainag
unilater
maxillari
toothach
facial
pain
unilater
tender
maxillari
sinu
improv
initi
worsen
time
accord
idsa
guidelin
clinic
symptom
sign
acut
bacteri
sinus
persist
day
without
improv
sever
symptom
sign
high
fever
c
last
day
purul
nasal
drainag
facial
tender
develop
onset
accord
guidelin
recommend
doubl
sicken
new
fever
headach
increas
nasal
drainag
begin
acut
viral
upper
respiratori
infect
symptom
begun
improv
day
symptom
onset
acut
bacteri
sinus
suspect
antibiot
therapi
initi
addit
foul
smell
discharg
suggest
anaerob
bacteri
infect
clinician
assess
possibl
tooth
infect
begin
antibiot
therapi
previou
rct
shown
antibiot
therapi
group
day
higher
rate
improv
placebo
group
durat
pain
morbid
correl
initi
treatment
acut
bacteri
sinus
therefor
antibiot
may
prescrib
primari
care
patient
acut
bacteri
sinus
without
complic
howev
clinician
may
also
delay
initi
antibiot
therapi
opt
watch
wait
approach
depend
case
hand
howev
earli
antibiot
therapi
delay
case
clinician
confid
patient
attend
followup
appoint
empir
antibiot
therapi
initi
case
patient
show
improv
symptom
symptom
worsen
within
day
proper
nonantibiot
ic
symptomat
treatment
diagnosi
acut
bacteri
sinus
empir
antibiot
therapi
also
initi
case
involv
symptom
find
suggest
sever
acut
bacteri
sinus
fever
c
higher
facial
pain
last
day
purul
nasal
drainag
fig
amoxicillin
amoxicillinclavulan
recommend
initi
empir
therapi
acut
bacteri
sinus
adult
qualiti
evid
high
strength
recommend
strong
high
dose
amoxicillin
amoxicillinclavulan
consid
patient
area
high
preval
penicillinresist
pneumonia
patient
sever
symptom
older
patient
patient
recent
hospit
admiss
patient
histori
antimicrobi
therapi
within
past
month
immunocompromis
patient
qualiti
evid
moder
strength
recommend
strong
patient
allerg
penicillin
patient
type
hypersensit
eg
rash
doxycyclin
fluoroquinolon
thirdgener
cephalosporin
clindamycin
may
consid
type
hypersensit
eg
anaphylaxi
betalactam
antibiot
eg
cephalosporin
use
nonbetalactam
antibiot
use
choos
appropri
antibiot
acut
bacteri
sinus
main
caus
pathogen
antibiot
suscept
must
consid
although
korean
epidemiolog
data
caus
pathogen
acut
bacteri
sinus
data
countri
show
pneumonia
h
influenza
catarrhali
aureu
common
pneumonia
h
influenza
account
isol
strain
howev
epidemiolog
chang
anticip
korea
respons
progress
rise
pneumococc
vaccin
rate
among
clinic
isol
taken
patient
visit
primari
care
clinic
sinus
unit
state
sensit
pneumonia
penicillin
azithromycin
levofloxacin
respect
wherea
sensit
h
influenza
azithromycin
levofloxacin
two
rct
one
systemat
literatur
review
pertain
possibl
firstlin
empir
antibiot
acut
sinus
accord
report
differ
clinic
treatment
outcom
sever
antibiot
includ
amoxicillin
cefuroxim
axetil
amoxicillinclavulan
levofloxacin
moxifloxacin
clarithromycin
patient
radiolog
bacteriolog
diagnos
acut
sinus
particular
consid
safeti
efficaci
price
narrowspectrum
amoxicillin
amoxicillinclavulan
amoxicillin
amoxicillinclavulan
amoxicillin
mgclavulan
mg
three
time
day
amoxicillin
mgclavulan
mg
twice
day
preferenti
consid
firstlin
empir
antibiot
acut
sinus
tabl
amoxicillinclavulan
may
prefer
amoxicillin
case
suspect
involv
antimirobialresist
bacteria
betalactamaseproduc
h
influenza
patient
show
moder
sever
infect
older
patient
patient
chronic
diseas
immunerel
diseas
although
adult
lower
risk
acut
bacteri
sinus
caus
catarrhali
children
catarrhali
resist
amoxicillin
suscept
amoxicillinclavulan
high
dose
amoxicillin
mgkgday
amoxicillin
clavulan
amoxicillin
g
mgkgday
twice
day
consid
follow
case
patient
live
area
high
preval
penicillinresist
pneumonia
endem
rate
patient
display
sever
symptom
high
fever
c
greater
possibl
suppur
complic
patient
older
year
patient
recent
histori
hospit
patient
histori
antibiot
therapi
within
past
month
patient
compromis
immun
patient
type
penicillin
allergi
eg
rash
doxycyclin
fluoroquinolon
thirdgener
cephalosporin
clindamycin
may
consid
patient
type
allergi
eg
anaphylaxi
betalactam
eg
cephalosporin
prohibit
nonbetalactam
use
eg
doxycyclin
clindamycin
fluoroquinolon
accord
metaanalysi
treatment
success
rate
use
fluoroquinolon
patient
without
penicillin
allergi
significantli
differ
use
betalactam
former
associ
higher
incid
advers
effect
foreign
data
reveal
main
pathogen
acut
sinus
name
pneumonia
h
influenza
highli
resist
macrolid
trimethoprimsulfamethoxazol
gener
recommend
durat
firstlin
empir
antibiot
adult
acut
bacteri
sinus
without
complic
day
day
improv
symptomssign
accord
review
rct
investig
durat
antibiot
therapi
patient
radiolog
diagnos
acut
sinus
signific
differ
treatment
success
rate
shortdur
antibiot
therapi
group
day
longdur
antibiot
therapi
group
day
antibiot
group
show
greater
incid
advers
drug
respons
nonantibiot
group
moreov
longdur
antibiot
therapi
group
day
higher
incid
advers
drug
respons
group
state
treatment
guidelin
children
addit
antibiot
may
administ
day
even
symptom
improv
antibiot
therapi
patient
delay
drug
respons
thu
firstlin
empir
antibiot
recommend
use
short
durat
within
day
day
improv
symptomssign
except
case
sever
acut
sinus
involv
high
fever
c
potenti
suppur
complic
tient
acut
bacteri
rhinosinus
symptom
worsen
within
hour
begin
initi
treatment
symptom
show
improv
even
day
begin
treatment
patient
reassess
term
accuraci
diagnosi
noninfecti
caus
antimicrobialresist
bacteria
presenc
structur
problem
imag
techniqu
paranas
sinu
plain
radiographi
ctmri
well
microbi
cultur
antimicrobi
resist
test
perform
reassess
best
perform
cultur
fine
needl
aspir
sinu
cultur
perform
use
sampl
taken
middl
nasal
meatu
via
nasal
endoscopi
cultur
use
nasopharyng
swab
recommend
patient
inde
diagnos
acut
bacteri
rhinosinus
reassess
initi
antibiot
therapi
patient
initi
place
watch
wait
chang
antibiot
patient
antibiot
therapi
although
best
choos
antibiot
accord
result
bacteri
cultur
suscept
test
case
empir
antibiot
warrant
use
highdos
amoxicillinclavulan
doxycyclin
clindamycinthirdgener
cephalosporin
treat
multidrugresist
pneumonia
betalactamaseproduc
h
influenza
catarrhali
follow
must
consid
secondlin
regimen
must
chosen
due
failur
initi
empir
antibiot
therapi
howev
lowdos
amoxicillinclavulan
chosen
initi
treatment
highdos
amoxicillinclavulan
therapi
may
use
cefaclor
cefprozil
secondgener
cephalosporin
recommend
common
pathogen
acut
bacteri
rhinosinus
name
pneumonia
h
influenza
catarrhali
low
suscept
antibiot
oral
cefditoren
cefcapen
cefpodoxim
report
efficaci
treat
acut
bacteri
rhinosinus
caus
penicillinresist
pneumonia
h
influenza
catarrhali
respect
oral
cefuroxim
cefdinir
known
effect
acut
bacteri
rhinosinus
caus
moder
penicillinresist
pneumonia
h
influenza
catarrhali
therapeut
efficaci
korea
uncertain
owe
high
proport
penicillinresist
pneumonia
countri
widen
microbiolog
spectrum
cover
anaerob
addit
use
metronidazol
clindamycin
recommend
cephalosporin
fluoroquinolon
levofloxacin
moxifloxacin
may
effect
possibl
resist
antibiot
among
myocobacterium
tuberculosi
pneumonia
note
note
fda
recommend
fluoroquinolon
use
sinus
bronchiti
urinari
tract
infect
without
complic
treatment
altern
canadian
british
studi
report
suscept
rate
pneumonia
h
influenza
catarrhali
doxycyclin
exce
doxycyclin
may
use
secondlin
antibiot
therapi
adult
acut
bacteri
rhinosinus
altern
fluoroquinolon
patient
difficulti
receiv
respond
initi
empir
antibiot
therapi
choic
support
pharmacokinet
superior
doxycyclin
find
doxycyclin
levofloxacin
differ
clinic
outcom
doxycyclin
associ
lower
medic
cost
patient
admit
commun
hospit
pneumonia
rais
concern
uncertain
therapeut
efficaci
macrolid
erythromycin
roxythromycin
azithromycin
clarithromycin
korea
due
high
proport
macrolidesresist
pneumonia
countri
although
telithromycin
ketolid
known
antibacteri
activ
macrolideresist
pneumonia
yet
viabl
option
korea
sever
case
acut
sinus
requir
hospit
follow
antibiot
may
use
ampicillinsulbactam
g
inject
everi
hour
ceftriaxon
g
inject
time
cefotaxim
g
inject
everi
hour
levofloxacin
mg
oralinject
moxifloxacin
mg
oral
iv
ceftriaxon
cefotaxim
found
act
strain
pneumonia
includ
penicillinresist
pneumonia
furthermor
preval
pneumonia
strain
continu
exhibit
rate
clindamycin
minimum
inhibitori
concentr
mic
mgl
levofloxacin
moxifloxacin
may
recommend
empir
therapi
patient
sever
condit
requir
hospit
rather
clindamycin
plu
ceftriaxon
addit
test
surgic
treatment
may
consid
symptom
worsen
without
improv
within
hour
proper
antibiot
therapi
ocular
central
nervou
system
complic
suspect
treatment
durat
gener
addit
day
improv
clinic
symptom
total
treatment
durat
gener
rang
day
regard
treatment
acut
bacteri
rhinosinus
health
insur
review
assess
servic
hira
suggest
gener
principl
antibiot
use
announc
choos
antibiot
base
drug
suscept
test
rather
indic
antibiot
phase
within
permit
rang
refer
patient
histori
case
sever
infect
oral
administr
alon
produc
adequ
treatment
outcom
parenter
inject
may
addit
use
patient
clinic
worsen
within
hour
fail
improv
day
initi
empir
antimicrobi
therapi
firstor
secondlin
regimen
case
patient
fail
show
improv
despit
appropri
firstand
secondlin
antibiot
therapi
includ
antibiot
therapi
case
defin
recurr
acut
sinus
four
episod
sinus
per
year
symptomfre
interv
differenti
diagnosi
consider
allerg
rhiniti
immun
abnorm
tooth
infect
recommend
surgic
treatment
may
consid
continu
episod
acut
sinus
accord
systemat
literatur
review
allergi
test
may
run
recurr
acut
sinus
chronic
sinus
allerg
patient
characterist
obstruct
natur
ostium
caus
edema
nasal
caviti
sinu
mucosa
particularli
ethmoid
sinu
sever
natur
ostia
suscept
allerg
sinus
nasal
polyp
patient
inde
posit
allergi
environment
therapi
immun
therapi
drug
therapi
may
consid
depend
patient
howev
limit
evid
support
environment
therapi
immun
therapi
effect
improv
clinic
outcom
recurr
acut
sinus
chronic
sinus
asthma
close
relat
recurr
acut
sinus
chronic
sinus
caus
frequent
recurr
episod
sinus
patient
diagnos
immunodefici
antibodi
defici
prophylact
antibiot
therapi
pneumococc
vaccin
regular
iv
igg
may
consid
addit
sinus
may
induc
dental
cari
extract
maxillari
molar
premolar
trauma
malnutrit
prolong
steroid
therapi
gener
weak
result
diabet
tumor
nasal
caviti
sinu
therefor
correspond
examin
perform
condit
suspect
presum
acut
bacteri
sinus
case
patient
fail
show
improv
recurr
inflamm
despit
appropri
treatment
requir
addit
test
nasal
endoscopi
radiolog
imag
referr
correspond
specialist
qualiti
evid
low
strength
recommend
weak
patient
suspect
orbit
intracrani
complic
acut
rhinosinus
immedi
refer
specialist
qualiti
evid
low
strength
recommend
strong
lack
improv
worsen
symptom
even
day
antibiot
therapi
acut
rhinosinus
consid
treatment
failur
exact
caus
identifi
patient
nonrespons
even
secondlin
antibiot
regimen
well
case
recurr
rhinosinus
defin
four
episod
acut
rhinosinus
per
year
symptomfre
interv
potenti
caus
includ
chronic
rhinosinus
allerg
rhiniti
abnorm
anatom
structur
within
nasal
caviti
reduc
immun
fungal
infect
granuloma
tumor
accur
differenti
caus
administr
appropri
treatment
patient
must
refer
specialist
perform
nasal
endoscopi
necessari
imag
test
ct
mri
paranas
sinus
close
proxim
orbit
later
base
skull
superiorli
therefor
infect
sinus
may
spread
orbit
cranium
caus
fatal
diseas
cellul
cerebromening
abscess
lack
proper
antibiot
therapi
surgic
drainag
may
lead
blind
brain
injuri
sever
case
death
sever
ocular
pain
periocular
edema
oculomotor
disabl
exophthalmo
purul
conjunct
reduc
visual
acuiti
patient
acut
rhinosinus
suggest
ocular
complic
wherea
high
fever
sever
headach
mening
irrit
sign
insan
suggest
intracrani
complic
patient
condit
must
refer
specialist
immedi
tabl
show
comparison
recommend
pertain
acut
sinus
present
guidelin
idsa
american
academi
otolaryngologyhead
neck
surgeri
american
academi
pediatr
korean
guidelin
antibiot
usag
children
acut
despit
high
preval
acut
uri
relev
research
good
evidencebas
find
critic
lack
furthermor
clinic
trial
use
basi
refer
guidelin
conduct
abroad
littl
research
data
involv
korean
patient
thu
requir
clinician
adequ
take
note
limit
util
guidelin
clinic
set
studi
involv
korean
subject
essenti
accumul
relev
data
make
appropri
revis
korean
guidelin
first
caus
pathogen
acut
uri
korean
adult
must
identifi
season
variat
virus
bacteria
proport
investig
minim
inappropri
use
antibiot
second
data
need
support
appropri
select
empir
antibiot
base
variou
pattern
antibiot
suscept
among
bacteri
strain
isol
patient
acut
bacteri
uri
third
studi
must
analyz
effect
rapid
antigen
test
use
pharyng
swab
bacteri
cultur
korean
adult
well
assess
use
cultur
use
sinusrel
specimen
addit
studi
also
assess
impact
relev
test
aso
creactiv
protein
procalcitonin
test
treatment
outcom
lay
foundat
develop
clinic
applic
diagnost
flowchart
fourth
studi
assess
therapeut
efficaci
amoxicillin
amoxicillinclavulan
recommend
guidelin
countri
firstlin
antibiot
korean
patient
also
compar
dose
treatment
durat
final
medic
profession
adher
guidelin
assess
estim
util
analyz
factor
hamper
adher
make
necessari
revis
guidelin
futur
furthermor
compar
actual
antibiot
prescrib
pattern
recommend
use
hira
insur
claim
data
may
also
provid
use
data
help
lower
inappropri
use
antibiot
acut
upper
respiratori
infect
guidelin
regularli
revis
keep
abreast
latest
key
research
find
korea
abroad
guidelin
support
research
program
fund
korea
center
diseas
control
prevent
kcdc
howev
kcdc
particip
develop
clinic
guidelin
guidelin
develop
committe
declar
conflict
interest
respect
government
agenc
pharmaceut
compani
hospit
interest
group
process
develop
guidelin
conflict
interest
http
shin
woo
kim
http
guidelin
korean
version
supplementari
materi
found
articl
onlin
http
supplementari
data
includ
one
tabl
found
articl
onlin
http
